The Latest on: Gene patents
[google_news title=”” keyword=”gene patents” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene patents
- Pfizer Gets FDA Approval For Rare Inherited Bleeding Disorder Gene Therapyon April 26, 2024 at 1:39 pm
In announcing its approval on Friday, the Food and Drug Administration said it had approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first gene therapy to ...
- FDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia Bon April 26, 2024 at 8:46 am
Developed by US pharma giant Pfizer (NYSE: PFE), Beqvez is authorized for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have ...
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024on April 25, 2024 at 1:02 pm
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of ...
- Meeting the cell and gene therapy scale-up challengeon April 25, 2024 at 9:00 am
One of the pivotal challenges in the development and commercialisation of cell and gene therapies (CGT) lies in scaling up production. This challenge is particularly pronounced as companies transition ...
- Gene Therapy For Ocular Rare Disease Pipeline Insight Report 2024on April 25, 2024 at 1:06 am
The "Gene Therapy For Ocular Rare Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights of present clinical ...
- HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECGon April 24, 2024 at 8:00 am
Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging. The ability to assess cardiac diastolic ...
- AstraZeneca and Merck's Lynparza set to 'dominate' PARP marketon April 24, 2024 at 5:23 am
AstraZeneca and Merck & Co. were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. | ...
- Moderna Investors Should Beware Patent-Dispute Fallouton April 23, 2024 at 11:40 am
Moderna's stock soared on positive cancer vaccine trial results, but legal troubles loom as a patent dispute threatens massive damages. Read my analysis here.
- USDA Grants Amfora Exemption for Its Patented, Gene-Edited, Ultra-High Protein Soy, Accelerating Path to Marketon April 23, 2024 at 5:16 am
The U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) has granted Amfora, Inc. an exemption for its gene-edited, ultra-high protein soybeans. The exemption is a ...
via Bing News